Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtypes of non-Hodgkin's lymphomas. Treatment-related complications, however, are considerable, and a common problem encountered is respiratory distress or respiratory insufficiency. Usually these difficulties have been attributed to infectious etiologies or to chemotherapy-induced interstitial fibrosis, most often involving bleomycin. We describe five patients presenting with respiratory problems several weeks after the initiation of chemotherapy. These patients, who represent 3 percent of all patients treated with a single bleomycin-containing regimen for intermediate or high grade non-Hodgkin's lymphoma, were all initially thought to have chemotherapy-induced interstitial fibrosis but were found on subsequent evaluation to have pulmonary emboli. Of the three patients in whom pulmonary emboli were diagnosed antemortem, two had symptoms suggestive of pulmonary emboli and all were successfully treated and remained well and free of lymphoma for over 24 months. Two additional patients were diagnosed at autopsy. We suggest that pulmonary emboli may contribute significantly to the morbidity and mortality of patients undergoing chemotherapy for non-Hodgkin's lymphoma and recommend that patients presenting with respiratory difficulties be evaluated for pulmonary emboli.
 ...
PMID:Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. 245 70

A 24-year-old man had a large anterior mediastinal mass and a nonproductive cough of 6 weeks' duration. With the patient under general anesthesia, a diagnostic mediastinoscopy was performed with endotracheal intubation. During the procedure, acute respiratory failure developed as a result of tracheal obstruction. Fiberoptic bronchoscopic examination of the patient in the supine position revealed almost total extrinsic compression of the trachea and no evidence of intraluminal disease. Reexamination of the trachea with the patient in sitting and semiprone positions showed resolution of the extrinsic compression and respiratory distress. Flow-volume curves obtained before treatment of the mediastinal mass (histologically diagnosed as Hodgkin's lymphoma) disclosed major airway compression with the patient in the supine position; the abnormality disappeared after chemotherapy. The mechanisms responsible for tracheal compression by mediastinal masses during general anesthesia may include the following: (1) the effect of anesthesia on pulmonary mechanics, (2) the supine body position, (3) the elimination of glottic regulation of airflow by endotracheal intubation, (4) changes related to the surgical manipulation of the tumor itself, (5) the size and location of the mediastinal mass, (6) the young age of the patient, and (7) preexisting airways disease. Anticipation and prevention of potential respiratory complications and preparedness to treat them appropriately are important aspects of the management of these patients.
 ...
PMID:Mediastinal mass and tracheal obstruction during general anesthesia. 317 49

Fifteen patients with lymphoid malignancies and tumour-related fever (greater than 38.0 degrees C) were given 50 mg indomethacin (IM) orally. This resulted in a reduction of body temperature in all cases (mean +/- SD 3.4 +/- 2.0 degrees C). In one patient with untreated Hodgkin's disease, temperature fell from 40.6 degrees C to 30.6 degrees C within 12 hours without any cardiovascular or respiratory distress. The lytic effect of IM on fever was more pronounced and more rapid in the 15 patients with lymphoma than in a group of 10 patients with acute myocardial infarction. IM therapy has a clear value in relieving tumour-associated fever in patients with malignant lymphoma. There may be a qualitative difference between the IM response of tumour-related fever and fever related to non-malignant diseases.
 ...
PMID:Antipyretic effect of indomethacin in malignant lymphoma. 348 41

Pneumocystis carinii is observed in the bone marrow of two adults immuno-compromised; the initial diseases are on the one hand a Hodgkin's disease, on the other hand a malignant lymphoma for immunocytoma type, which necessitate heavy and invalidating treatments. A Pneumocystis carinii pneumonia with respiratory distress seems to have carrying away two patients death. Eventually pathogenic part of the parasite in the bone marrow localization.
 ...
PMID:[Pneumocystis carinii in the bone marrow]. 387 33

Fluorescence polarization of the amniotic fluid from 39 high risk pregnancies requiring preterm delivery was measured in order to assess the maturity of the fetal lung. The study population included 15 cases of intrauterine growth retardation, ten maternal hypertension, five maternal Hodgkin's disease, three placenta previa, two fetal malformation, two polyamnios, one untreated diabetes, one maternal nephropathy. All patients underwent a single amniocentesis before deciding whether to deliver a preterm baby and FP of the amniotic fluid was done within two hours from amniocentesis. In five cases this was > 0.311, the cut-off limit taken as an indicator of fetal pulmonary status, and three of these developed respiratory distress syndrome. In 34 cases FP values were < or = 0.311; in spite of the apparent lung maturity two of these newborns developed respiratory distress syndrome. On the basis of these results the FP sensitivity was calculated as 60%, specificity 94% and the overall accuracy 90%.
 ...
PMID:Fetal lung maturity evaluation with fluorescence polarization of the amniotic fluid. 812 30

Toxic effect of chemotherapy was found in 13 dead patients suffering from myeloic leukaemia, Hodgkin disease and malignant lymphoma during past 18 months. Drugs with known toxicity from various sorts of antineoplastic treatment were administered simultaneously or successively what did not allow to differentiate their effects. Clinical symptomatology of the patients comprised respiratory distress syndrome or heart failure which could not be otherwise explained. Pneumopathies prevailed (10 cases) over isolated cardiomyopathies (3 cases), their concurrence was found in 3 other cases. Pneumopathies were mostly (9 cases) characterized by diffuse alveolar damage, by often bizarre proliferating type II pneumocytes and capillary thrombi. Simultaneous organizing processes (7 cases) in alveoli and bronchioli were present and sometimes combined with interstitial lung fibrosis; a single secondary alveolar lipoproteinosis was combined with intraalveolar organization. Cardiomyopathies were mostly characterized by irregular cardiocyte hypertrophy and focal fibrosis, sometimes by distended and waved or vacuolated cardiocytes. Toxic lesions are reversible as usual and risky treatment modalities found out by pathologist are to be early modified.
 ...
PMID:[Toxic manifestations in the treatment of leukemias and malignant lymphomas]. 831 82

A 24-year-old woman with recurrent Hodgkin's lymphoma, stage IIB nodular sclerosing type, underwent an autologous bone marrow transplantation. Forty-five days after transplantation, an upper respiratory tract infection developed that progressed to respiratory distress necessitating mechanical ventilation. An open-lung biopsy demonstrated diffuse alveolar damage. After an extensive search for the cause of the respiratory compromise, we detected respiratory syncytial virus in a bronchoalveolar lavage specimen. The patient was immediately treated with aerosolized ribavirin and intravenous immunoglobulin; her symptoms resolved, and she was extubated 4 days after initiation of therapy.
 ...
PMID:Respiratory syncytial virus pneumonitis-induced diffuse alveolar damage in an autologous bone marrow transplant recipient. 947 99

The use of high-dose therapy (HDT) and autologous hematopoietic cell transplantation (AHCT) for children and adolescents with primary refractory and relapsed Hodgkin's disease is increasing. The purpose of this retrospective analysis was to: (1) evaluate the outcome of HDT and AHCT in pediatric patients with Hodgkin's disease, and (2) identify factors that predispose patients to the development of transplantation-related complications. We describe the experiences of 34 pediatric patients from a single institution with primary refractory or relapsed Hodgkin's disease. HDT regimens consisted of cyclophosphamide and etoposide combined with either carmustine, chloroethylcyclohexylnitrosurea, or fractionated total body irradiation. Kaplan-Meier survival predicts that 67% (95% confidence interval [CI] 47%-87%) of patients will be alive and disease-free at 5 years. Nine patients had disease recurrence, of whom 5 relapsed after 1 year (1.5-6.3 years). Five patients succumbed to treatment-related toxicities, of whom 4 died of pulmonary failure. Fifteen patients (44%) developed post-AHCT idiopathic diffuse lung injury syndrome: acute alveolitis (n = 2); diffuse alveolar hemorrhage (n = 2); acute respiratory distress syndrome (n = 2); delayed interstitial pneumonitis (n = 8); and bronchiolitis obliterans (n = 1). The following factors did not predict for the development of a diffuse lung injury syndrome in univariate analysis: prior treatment with bleomycin, pre-HDT pulmonary function tests, and prior thoracic irradiation. Of the patients in our cohort, 44% had a history of atopy (allergic rhinitis and/or asthma). Multivariate logistic analysis revealed that a preexisting history of atopy was highly predictive of idiopathic pulmonary complications (P = .0001, odds ratio = 21, CI 3.6-125). Our experience shows that HDT followed by AHCT results in durable remissions in two thirds of pediatric patients with refractory and relapsed Hodgkin's disease, and a history of atopy is associated with post-AHCT pulmonary complications.
 ...
PMID:High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes. 1121 99

In contrast to solid organ transplantation (Tx), the incidence of post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell Tx (HSCT) is generally low. This risk, however, is significantly elevated in patients receiving human leukocyte antigen (HLA) mis-matched or T-cell-depleted grafts, or after treatment for severe graft-versus-host disease (GvHD). An 18-yr-old patient with positive Epstein-Barr virus (EBV) serology received a fully matched, unmanipulated bone marrow graft from an unrelated EBV-positive donor for treatment of acute myeloid leukemia (AML) in second complete remission. GvHD prophylaxis was performed with cyclosporin A (CsA) and a short course of methotrexate. Four months after Tx, the patient developed ulcerative tonsillitis that was unresponsive to antibiotic treatment. Diarrhea appearing simultaneously was interpreted as gastrointestinal GvHD and steroids were added to CsA. A few days later the patient was admitted to hospital because of generalized seizure and pneumonia. Despite reduction of immunosuppression, intensification of anti-viral treatment, and subsequent mechanical ventilation, the patient died of acute respiratory distress 6 days later. Autopsy demonstrated disseminated EBV-induced, multi-nodular lymphoma infiltration of the entire colon but no signs of GvHD. Moreover, both lungs, paratracheal lymph nodes, kidneys, thyroid gland, and liver were infiltrated with large B-cell non-Hodgkin's lymphomas. This case underlines the rapid and aggressive course of EBV-induced disseminated PTLD after HSCT, initially mimicking intestinal GvHD because of massive colonic lymphoma infiltration. Tissue biopsies should be performed early for establishing correct diagnosis, thus enabling specific therapy, e.g. infusion of donor leukocytes with cytotoxic T-lymphocytes.
 ...
PMID:Epstein-Barr virus-associated post-transplant lymphoproliferative disease after bone marrow transplantation mimicking graft-versus-host disease. 1127 9

A 45 years old male in whom a Hodgkin disease, nodular sclerosis variety, IIIBS, with splenectomy was diagnosed at the age of 27 years of age, is reported. He was treated initially with chemotherapy C-MOPP and radiotherapy, obtaining a complete remission of the disease two years later. In December 2000, after 17 years of remission, the disease relapsed with generalized lymph node enlargement and lung involvement. He was treated with ABVD chemotherapy, but died after 5 cycles due to a febrile neutropenia, bronchopneumonia and respiratory distress.
 ...
PMID:[Relapse of Hodgkin disease after 17 years of complete remission. A case report]. 1270 59


1 2 3 Next >>